LOS ANGELES--(BUSINESS WIRE)--April 10, 2006--CytRx Corporation (Nasdaq: CYTR - News) today announced that its small molecule drug candidate arimoclomol was cited in the fifth annual report on “100 Great Investigational Drugs in Development,” published in the March 2006 issue of the pharmaceutical industry magazine R&D Directions. According to the publication, compounds on this list distinguish themselves as “innovative, first-in-class or clearly advanced compared with those on the market.” CytRx is currently conducting a Phase II clinical trial at ten centers across the U.S. with arimoclomol in amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig’s disease, a devastating neurodegenerative disease with no effective treatment.
